Simultaneous Overexpression of miR-126 and miR-34a Induces a Superior Antitumor Efficacy in Pancreatic Adenocarcinoma [Retraction]

MLA

Feng SD, et al. “Simultaneous Overexpression of MiR-126 and MiR-34a Induces a Superior Antitumor Efficacy in Pancreatic Adenocarcinoma [Retraction].” OncoTargets and Therapy, Mar. 2020, pp. 2125–26. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doajarticles..8a41e04787b26ea4672fba7709fb0b1b&authtype=sso&custid=ns315887.

APA

Feng SD, Mao ZM, Liu CY, Nie YS, Sun B, Guo MG, & Su CQ. (2020). Simultaneous Overexpression of miR-126 and miR-34a Induces a Superior Antitumor Efficacy in Pancreatic Adenocarcinoma [Retraction]. OncoTargets and Therapy, 2125–2126.

Chicago

Feng SD, Mao ZM, Liu CY, Nie YS, Sun B, Guo MG, and Su CQ. 2020. “Simultaneous Overexpression of MiR-126 and MiR-34a Induces a Superior Antitumor Efficacy in Pancreatic Adenocarcinoma [Retraction].” OncoTargets and Therapy, March, 2125–26. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doajarticles..8a41e04787b26ea4672fba7709fb0b1b&authtype=sso&custid=ns315887.